Yanfeng Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yanfeng Wang has a total of 43 co-authors. Here are the top co-authors by number of shared publications:
- Zhenghao Huo
Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China
3 shared publications - Hong Zhu
Department of Rheumatology, General Hospital of Ningxia Medical University, Yinchuan, China
2 shared publications - Jie Dang
Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China
2 shared publications Jing Zhang
Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China
2 shared publications- Pengfei Luan
Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China
2 shared publications - Qian Ma
Department of Medical Genetics and Cell Biology, College of Basic Medicine, Ningxia Medical University, Yinchuan, Ningxia, China
2 shared publications
Latest Publications
- 4 May 2026
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 138 (6) , e70242
The Cardiovascular Safety of Antiparkinsonian Drugs—Analysis of Signals in the FDA Adverse Event Report System Database
Objective: This study aimed to investigate the characteristics and spectrum of cardiotoxicity induced by various antiparkinsonian drugs based on the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. Methods: Data from the FAERS database from the first quarter of 2004 to the third quarter of 2025 were downloaded for disproportionality analysis. We employed validated disproportionality metrics including the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN) and multi‐item gamma Poisson shrinker (MGPS) to detect significant drug‐event associations. Results: After removing duplicates, a total of 42 583 cases of patients treated with antiparkinsonian drugs were included in the FAERS database. Dopamine receptor agonists exhibited the most extensive range of cardiac adverse events. Monoamine oxidase B inhibitors displayed the second broadest range of toxicity. As for catechol‐O‐methyltransferase inhibitors, a total of six signals were detected in entacapone. Four signals were detected for amantadine, while no signals were identified for levodopa. Conclusion: This study highlights the cardiovascular adverse reactions associated with Parkinson's treatment drugs. These findings underscore the importance of monitoring and evaluating the cardiovascular safety of antiparkinsonian medications.
- 4 May 2026
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 138 (6) , e70242
The Cardiovascular Safety of Antiparkinsonian Drugs—Analysis of Signals in the FDA Adverse Event Report System Database
Objective: This study aimed to investigate the characteristics and spectrum of cardiotoxicity induced by various antiparkinsonian drugs based on the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) database. Methods: Data from the FAERS database from the first quarter of 2004 to the third quarter of 2025 were downloaded for disproportionality analysis. We employed validated disproportionality metrics including the reporting odds ratio (ROR), proportional reporting ratio (PRR), Bayesian confidence propagation neural network (BCPNN) and multi‐item gamma Poisson shrinker (MGPS) to detect significant drug‐event associations. Results: After removing duplicates, a total of 42 583 cases of patients treated with antiparkinsonian drugs were included in the FAERS database. Dopamine receptor agonists exhibited the most extensive range of cardiac adverse events. Monoamine oxidase B inhibitors displayed the second broadest range of toxicity. As for catechol‐O‐methyltransferase inhibitors, a total of six signals were detected in entacapone. Four signals were detected for amantadine, while no signals were identified for levodopa. Conclusion: This study highlights the cardiovascular adverse reactions associated with Parkinson's treatment drugs. These findings underscore the importance of monitoring and evaluating the cardiovascular safety of antiparkinsonian medications.
- Open Access
- 6 December 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 106, 106898
Investigating the causality and pathogenesis of multiple sclerosis in breast cancer via bioinformatics analysis
- 6 December 2025
- Published by Elsevier in Multiple Sclerosis and Related Disorders
- Vol. 106, 106898
Open AccessInvestigating the causality and pathogenesis of multiple sclerosis in breast cancer via bioinformatics analysis
- Open Access
- 3 March 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (8) , 988-990
Immune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
An abstract is unavailable. This article is available as a PDF only.
- 3 March 2022
- Published by Wolters Kluwer Health in Chinese Medical Journal
- Vol. 135 (8) , 988-990
Open AccessImmune checkpoint inhibitors-associated cardiotoxicity in immunotherapy trials on gastrointestinal cancer patients
An abstract is unavailable. This article is available as a PDF only.
- Open Access
- 4 September 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-2
Corrigendum to “miR-183-5p Is a Potential Molecular Marker of Systemic Lupus Erythematosus”
[This corrects the article DOI: 10.1155/2021/5547635.].
- 4 September 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-2
Open AccessCorrigendum to “miR-183-5p Is a Potential Molecular Marker of Systemic Lupus Erythematosus”
[This corrects the article DOI: 10.1155/2021/5547635.].
- Open Access
- 25 June 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (25) , e26499
Identification of hub genes, pathways, and related transcription factors in systemic lupus erythematosus
Background: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ damage and the production of a variety of autoantibodies. The pathogenesis of SLE has not been fully defined, and it is difficult to treat. Our study aimed to identify candidate genes that may be used as biomarkers for the screening, diagnosis, and treatment of SLE. Methods: We used the GEO2R tool to identify the differentially expressed genes (DEGs) in SLE-related datasets retrieved from the Gene Expression Omnibus (GEO). In addition, we also identified the biological functions of the DEGs by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. Additionally, we constructed protein–protein interaction (PPI) networks to identify hub genes, as well as the regulatory network of transcription factors related to DEGs. Results: Two datasets were identified for use from the GEO (GSE50772, GSE4588), and 34 up-regulated genes and 4 down-regulated genes were identified by GEO2R. Pathway analysis of the DEGs revealed enrichment of the interferon alpha/beta signaling pathway; GO analysis was mainly enriched in response to interferon alpha, regulation of ribonuclease activity. PPIs were constructed through the STRING database and 14 hub genes were selected and 1 significant module (score = 12.923) was obtained from the PPI network. Additionally, 11 key transcription factors that interacted closely with the 14 hub DEGs were identified from the gene transcription factor network. Conclusions: Bioinformatic analysis is an effective tool for screening the original genomic data in the GEO database, and a large number of SLE-related DEGs were identified. The identified hub DEGs may be potential biomarkers of SLE.
- 25 June 2021
- Published by Wolters Kluwer Health in Medicine
- Vol. 100 (25) , e26499
Open AccessIdentification of hub genes, pathways, and related transcription factors in systemic lupus erythematosus
Background: Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by multiple organ damage and the production of a variety of autoantibodies. The pathogenesis of SLE has not been fully defined, and it is difficult to treat. Our study aimed to identify candidate genes that may be used as biomarkers for the screening, diagnosis, and treatment of SLE. Methods: We used the GEO2R tool to identify the differentially expressed genes (DEGs) in SLE-related datasets retrieved from the Gene Expression Omnibus (GEO). In addition, we also identified the biological functions of the DEGs by gene ontology (GO) and Kyoto Encyclopedia of Genes and Genomes pathway enrichment analysis. Additionally, we constructed protein–protein interaction (PPI) networks to identify hub genes, as well as the regulatory network of transcription factors related to DEGs. Results: Two datasets were identified for use from the GEO (GSE50772, GSE4588), and 34 up-regulated genes and 4 down-regulated genes were identified by GEO2R. Pathway analysis of the DEGs revealed enrichment of the interferon alpha/beta signaling pathway; GO analysis was mainly enriched in response to interferon alpha, regulation of ribonuclease activity. PPIs were constructed through the STRING database and 14 hub genes were selected and 1 significant module (score = 12.923) was obtained from the PPI network. Additionally, 11 key transcription factors that interacted closely with the 14 hub DEGs were identified from the gene transcription factor network. Conclusions: Bioinformatic analysis is an effective tool for screening the original genomic data in the GEO database, and a large number of SLE-related DEGs were identified. The identified hub DEGs may be potential biomarkers of SLE.
- Open Access
- 6 May 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-11
miR-183-5p Is a Potential Molecular Marker of Systemic Lupus Erythematosus
Objective. To investigate microRNA (miRNA) expression profiles in individuals with systemic lupus erythematosus (SLE) and identify the valuable miRNA biomarkers in diagnosing and monitoring SLE. Methods. Next-generation sequencing (NGS) was performed to assess miRNA amounts in peripheral blood mononuclear cells (PBMCs) from four SLE cases and four healthy controls. Quantitative polymerase chain reaction (qPCR) was carried out for validating candidate miRNAs in 32 SLE cases and 32 healthy controls. In addition, receiver operating characteristic (ROC) curve analysis was completed to evaluate diagnostic performance. Finally, the associations of candidate miRNAs with various characteristics of SLE were analyzed. Results. A total of 157 miRNAs were upregulated, and 110 miRNAs were downregulated in PBMCs from SLE cases in comparison to healthy controls, of which the increase of miR-183-5p and decrease of miR-374b-3p were validated by qPCR and both showed good diagnostic performance for SLE diagnosis. Besides, miR-183-5p expression levels displayed a positive association with SLE disease activity index (SLEDAI) and anti-dsDNA antibody amounts. Conclusion. Our data indicated that miR-183-5p is a promising biomarker of SLE.
- 6 May 2021
- Published by Wiley in Journal of Immunology Research
- Vol. 2021, 1-11
Open AccessmiR-183-5p Is a Potential Molecular Marker of Systemic Lupus Erythematosus
Objective. To investigate microRNA (miRNA) expression profiles in individuals with systemic lupus erythematosus (SLE) and identify the valuable miRNA biomarkers in diagnosing and monitoring SLE. Methods. Next-generation sequencing (NGS) was performed to assess miRNA amounts in peripheral blood mononuclear cells (PBMCs) from four SLE cases and four healthy controls. Quantitative polymerase chain reaction (qPCR) was carried out for validating candidate miRNAs in 32 SLE cases and 32 healthy controls. In addition, receiver operating characteristic (ROC) curve analysis was completed to evaluate diagnostic performance. Finally, the associations of candidate miRNAs with various characteristics of SLE were analyzed. Results. A total of 157 miRNAs were upregulated, and 110 miRNAs were downregulated in PBMCs from SLE cases in comparison to healthy controls, of which the increase of miR-183-5p and decrease of miR-374b-3p were validated by qPCR and both showed good diagnostic performance for SLE diagnosis. Besides, miR-183-5p expression levels displayed a positive association with SLE disease activity index (SLEDAI) and anti-dsDNA antibody amounts. Conclusion. Our data indicated that miR-183-5p is a promising biomarker of SLE.
- Open Access
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1) , 1503403
miR‐149 Suppresses the Proliferation and Metastasis of Human Gastric Cancer Cells by Targeting FOXC1
Purpose. Gastric cancer is one of the most common cancers in the world. miRNAs play an important role in regulating gene expression by binding with 3 ′‐UTR of the target gene. The aim of this study was to investigate the function of miRNA‐149 and FOXC1 in gastric cancer. Patients and Methods. qRT‐PCR was used to detect the expression of miRNA‐149 and FOXC1 in gastric cancer tissues and cells. Human gastric cancer cell lines AGS and MKN28 were cultured and transfected with miR‐149 overexpression plasmid and its control or FOXC1 siRNA and its control. The MTT, colony formation, flow cytometry, wound healing, transwell, and western blotting were performed to examine the function of miRNA‐149 and FOXC1 in the development of gastric cancer. What is more, dual‐luciferase assay and western blotting were used to demonstrated the relationship between miRNA‐149 and FOXC1. Results. miRNA‐149 was underexpressed in gastric cancer tissues and cells, while overexpression of miRNA‐149 promoted cell apoptosis, retarded cell cycle, and inhibited proliferation and migration in AGS and MKN28 cells. In addition, we showed that miRNA‐149 targeted FOXC1. What is more, FOXC1 was highly expressed in gastric cancer tissues and cells; the silencing of FOXC1 inhibited the biological function of AGS and MKN28 cells. Conclusion. miRNA‐149 inhibits the biological behavior of gastric cancer by targeting FOXC1, providing a promising target in the treatment of human gastric cancer.
- 1 January 2021
- Published by Wiley in BioMed Research International
- Vol. 2021 (1) , 1503403
Open AccessmiR‐149 Suppresses the Proliferation and Metastasis of Human Gastric Cancer Cells by Targeting FOXC1
Purpose. Gastric cancer is one of the most common cancers in the world. miRNAs play an important role in regulating gene expression by binding with 3 ′‐UTR of the target gene. The aim of this study was to investigate the function of miRNA‐149 and FOXC1 in gastric cancer. Patients and Methods. qRT‐PCR was used to detect the expression of miRNA‐149 and FOXC1 in gastric cancer tissues and cells. Human gastric cancer cell lines AGS and MKN28 were cultured and transfected with miR‐149 overexpression plasmid and its control or FOXC1 siRNA and its control. The MTT, colony formation, flow cytometry, wound healing, transwell, and western blotting were performed to examine the function of miRNA‐149 and FOXC1 in the development of gastric cancer. What is more, dual‐luciferase assay and western blotting were used to demonstrated the relationship between miRNA‐149 and FOXC1. Results. miRNA‐149 was underexpressed in gastric cancer tissues and cells, while overexpression of miRNA‐149 promoted cell apoptosis, retarded cell cycle, and inhibited proliferation and migration in AGS and MKN28 cells. In addition, we showed that miRNA‐149 targeted FOXC1. What is more, FOXC1 was highly expressed in gastric cancer tissues and cells; the silencing of FOXC1 inhibited the biological function of AGS and MKN28 cells. Conclusion. miRNA‐149 inhibits the biological behavior of gastric cancer by targeting FOXC1, providing a promising target in the treatment of human gastric cancer.